REG1V Share Price | Revenio Group Oyj Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Revenio Group Oyj with Similar Stocks

Bioretec Ltd.Biohit Oyj Nexstim Oyj

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 489 Million ()

P/E

27.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.02

Return on Equity

15.17%

Price to Book

4.26

Revenue and Profits:

Net Sales:

31 Million

(Quarterly Results - Dec 2025)

Net Profit:

6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.92%

6 Months

19.92%

1 Year

19.92%

2 Years

33.58%

3 Years

49.37%

4 Years

115.42%

5 Years

175.33%

Revenio Group Oyj for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

12.42%

EBIT Growth (5y)

5.99%

EBIT to Interest (avg)

22.40

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

0.84

Tax Ratio

24.71%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

30.11%

ROE (avg)

21.01%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.10

EV to EBIT

17.77

EV to EBITDA

15.16

EV to Capital Employed

4.66

EV to Sales

4.13

PEG Ratio

Dividend Yield

ROCE (Latest)

26.23%

ROE (Latest)

15.17%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 2.30% vs 4.81% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -16.67% vs -8.33% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.20",
          "val2": "30.50",
          "chgp": "2.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.80",
          "val2": "10.00",
          "chgp": "-22.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.50",
          "val2": "6.60",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "214.70%",
          "val2": "291.80%",
          "chgp": "-7.71%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.99% vs 7.14% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -5.95% vs -3.14% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "109.70",
          "val2": "103.50",
          "chgp": "5.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29.70",
          "val2": "29.90",
          "chgp": "-0.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.70",
          "chgp": "-42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.40",
          "val2": "18.50",
          "chgp": "-5.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "229.60%",
          "val2": "238.60%",
          "chgp": "-0.90%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

31.20

30.50

2.30%

Operating Profit (PBDIT) excl Other Income

7.80

10.00

-22.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

5.50

6.60

-16.67%

Operating Profit Margin (Excl OI)

214.70%

291.80%

-7.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 2.30% vs 4.81% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -16.67% vs -8.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

109.70

103.50

5.99%

Operating Profit (PBDIT) excl Other Income

29.70

29.90

-0.67%

Interest

0.40

0.70

-42.86%

Exceptional Items

0.00

Consolidate Net Profit

17.40

18.50

-5.95%

Operating Profit Margin (Excl OI)

229.60%

238.60%

-0.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 5.99% vs 7.14% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -5.95% vs -3.14% in Dec 2024

All Annual Results

Company CV

About Revenio Group Oyj

Revenio Group Oyj

Pharmaceuticals & Biotechnology

Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.

Company Coordinates

Company Details

Ayritie 22 , VANTAA None : 01510

Tel: 358 9 87751150

https://www.reveniogroup.fi/

Registrar Details